Clinical Trials
90 trialsNCT02427620 2026-05-22
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03646461 2026-05-22
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
University of California, San Diego
Phase 2 Terminated
NCT06271616 2026-05-22
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
Mayo Clinic
Phase 2 Terminated
NCT02007044 2026-05-20
Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04802590 2026-05-20
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Active not recruiting
NCT03710772 2026-05-19
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04263480 2026-05-12
CZAR-1
University of Ulm
Phase 2 Active not recruiting
NCT04273139 2026-05-11
Ibrutinib + Venetoclax in Untreated WM
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03506373 2026-05-05
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Mayo Clinic
Phase 2 Terminated
NCT01589302 2026-04-13
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04450173 2026-04-13
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
University of California, Davis
Phase 2 Active not recruiting
NCT03478514 2026-04-09
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
Alliance Foundation Trials, LLC.
Phase 2 Active not recruiting
NCT03697512 2026-04-08
MALIBU
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Active not recruiting
NCT02997761 2026-04-07
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
University of California, Davis
Phase 2 Completed
NCT02518555 2026-04-06
Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT02682641 2026-03-27
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Active not recruiting
NCT03282396 2026-03-20
Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02629809 2026-03-06
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03514017 2026-03-02
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01880567 2026-02-19
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02756897 2026-02-19
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03198026 2026-02-19
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
Thomas Jefferson University
Phase 2 Active not recruiting
NCT02649387 2026-02-10
MERIT
Mayo Clinic
Phase 2 Completed
NCT03513562 2026-02-06
Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03708003 2025-12-30
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Swiss Cancer Institute
Phase 2 Terminated
NCT04230304 2025-12-30
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Mayo Clinic
Phase 2 Terminated
NCT03620903 2025-12-05
Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
University of Ulm
Phase 2 Active not recruiting
NCT02666898 2025-11-26
ICLL07GAI
French Innovative Leukemia Organisation
Phase 2 Completed
NCT03734198 2025-11-26
IDA53
French Innovative Leukemia Organisation
Phase 2 Active not recruiting
NCT06958705 2025-11-25
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT03128879 2025-11-21
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT02251548 2025-10-24
iFCR
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03207555 2025-09-02
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04685915 2025-05-22
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT02744612 2025-03-26
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Completed
NCT02824029 2025-02-17
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT02388048 2025-01-29
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT02643667 2025-01-08
Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
Washington University School of Medicine
Phase 2 Completed
NCT02207062 2025-01-07
Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
University of Washington
Phase 2 Completed
NCT04234061 2024-11-07
TARMAC
Peter MacCallum Cancer Centre, Australia
Phase 2 Active not recruiting
NCT02692248 2024-10-10
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT02532257 2024-09-24
Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT06482684 2024-07-01
CARMAN
Ludwig-Maximilians - University of Munich
Phase 2 Recruiting
NCT02420912 2024-03-20
Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02451111 2024-03-13
Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
Swiss Cancer Institute
Phase 2 Terminated
NCT02242097 2024-03-12
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Northwestern University
Phase 2 Unknown
NCT03399513 2024-01-05
R-CHOEP-brut
University Hospital Muenster
Phase 2 Completed
NCT02332980 2024-01-03
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Mayo Clinic
Phase 2 Completed
NCT05694312 2023-12-01
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Recruiting
NCT02869633 2023-10-23
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Phase 2 Completed